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Abstract: 
Counterfeit medicines represent a global public health threat warranting 
the development of accurate, rapid and non-destructive methods for 
their identification. Portable near-infrared spectroscopy near-infrared 
spectroscopy offers this advantage. This work sheds light on the 
potential of combining NIRS with Principal Component Analysis (PCA) 
and Soft Independent Modelling of Class Analogy (SIMCA) for
authenticating branded and generic antibiotics. A total of 23 antibiotics 
were measured ‘non-destructively’ using a portable NIR spectrometer.
The antiobiotics corresponded to six different active pharmaceutical 
ingredients being: amoxicillin trihydrate and clavulanic acid;
azithromycin dihydrate; ciprofloxacin hydrochloride; doxycycline 
hydrochloride and ofloxacin.  NIR Spectra where exported into Matlab R
2018b where data analysis was applied. The results showed that the NIR
spectra of the medicines showed characteristic features corresponds to 
the main excipient(s). When combined with PCA, NIRS could distinguish 
between branded and generic medicines and could classify medicines 
according to their manufacturing sources. The PCA scores showed the
distinct clusters corresponding to each group of antibiotics whereas the 
loadings indicated which spectral features were significant. SIMCA 
provided more accurate classification over PCA for all antibiotics except 
ciprofloxacin which products shared many overlapping excipients. In 
summary, the findings of the study demonstrated the feasibility of 
portable NIRS as an initial method for screening antibiotics. 
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Abstract 
Counterfeit medicines represent a global public health threat warranting the 
development of accurate, rapid and non-destructive methods for their identification. 
Portable near-infrared spectroscopy near-infrared spectroscopy offers this advantage. 
This work sheds light on the potential of combining NIRS with Principal Component 
Analysis (PCA) and Soft Independent Modelling of Class Analogy (SIMCA) for 
authenticating branded and generic antibiotics. A total of 23 antibiotics were measured 
‘non-destructively’ using a portable NIR spectrometer. The antiobiotics corresponded 
to six different active pharmaceutical ingredients being: amoxicillin trihydrate and 
clavulanic acid; azithromycin dihydrate; ciprofloxacin hydrochloride; doxycycline 
hydrochloride and ofloxacin. NIR Spectra where exported into Matlab R 2018b where
data analysis was applied. The results showed that the NIR spectra of the medicines 
showed characteristic features corresponds to the main excipient(s). When combined 
with PCA, NIRS could distinguish between branded and generic medicines and could
classify medicines according to their manufacturing sources. The PCA scores showed 
the distinct clusters corresponding to ach group of antibiotics whereas the loadings 
indicated which spectral features were significant. SIMCA provided more accurate 
classification over PCA for all antibiotics except ciprofloxacin which products shared 
many overlapping excipients. In summary, the findings of the study demonstrated the 
feasibility of portable NIRS as an initial method for screening antibiotics.
Keywords 
Counterfeit medicines; antibiotics; near-infrared spectroscopy; principal component 
analysis; soft independent modelling of class analogy 
Introduction 
Medicine counterfeiting represents a global expanding problem with increased 
morbidity and mortality worldwide. The impact of counterfeit medicines can result 
in lethal consequences in its worst. A counterfeit medicine is defined by the World 
Health Organization (WHO) as “deliberately/fraudulently misrepresent their 
2 
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identity, composition or source” [1]. A substandard medicine is also known as poor 
quality medicine that fail to satisfy its manufacturing specifications [1-3]. 
Medicine counterfeiting can occur to any class of medicines, of any formulation 
and of any source. Antibiotics represent one of the main classes of medicines sold 
in both developed and developing countries; thus, have high probability of being 
substandard or counterfeited [4-8]. Counterfeit and substandard antibiotics may 
not be limited to the lack of active pharmaceutical ingredients (APIs) but also may 
have defects in their excipients’ constituents or in their physical characteristics .The 
consequences of using counterfeit antibiotics can range from decreased efficacy 
[9,10]; treatment failure [11-14]; antimicrobial resistance development [5,15]; 
and/or lethal consequences [10,15-16]. 
The literature revealed various methods for antibiotics authentication. These 
methods range from simple color tests to mass spectrometric methods. Color tests 
and thin layer chromatography have been used for detecting macrolides [17]; 
amoxicillin and co-trimoxazole [18]; and fluoroquinolones [19]. Likewise, 
inexpensive test cards were used for determination of beta-lactam antibiotics [20]. 
Color tests were also used alongside both the dissolution testing and the Global 
Pharma Health Fund (GPHF) Minilab for screening of specific classes of antibiotics 
such as amoxicillin and co-trimoxazole [18] and/or multiple classes [21,22]. More 
sophisticated techniques used for analysis of counterfeit and substances 
antibiotics included high performance liquid chromatography [18,23-25], ultra-high 
performance liquid chromatography [26], liquid chromatography mass 
spectrometry [27] and capillary electrophoresis [28]. 
However, all the aforementioned techniques were destructive to the samples 
analysed and/or required extensive method development. Portable near-infrared 
spectroscopy (NIRS) offers an advantage over the previous mentioned techniques 
in being rapid, mobile, and non-destructive. NIRS offers a further advantage over 
alternative chemical techniques in being able to characterize the physical 
properties alongside the chemical characteristics of the samples analyzed. Limited 
studies utilized NIRS for authenticating antibiotics such as ciprofloxacin [29,30]; 
fluoroquinolones [31]; macrolides [32]. However, the three aforementioned studies 
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focused on one class of antibiotics and utilized one multivariate data analysis 
algorithm at a time. Thus, there is still a need to look at a collective method that 
can authenticate diverse classes of antibiotics synchronously. This work aimed to 
evaluate NIRS and multivariate classification algorithms for authentication of 
antibiotics purchased worldwide. 
Theory 
Spectral pre-treatment 
Multiplicative Scatter Correction – First Derivative (MSC-D1) spectral pre-
treatment approach was applied in order to correct for the offset and baseline in 
the spectra that changes depending on several factors including the sample age, 
thickness and optical properties; temperature; moisture content; and performance 
of the instrument [33,34]. MSC corrected the offset of the scattered light by 
construction of a new spectrum that is a linear combination of the original spectrum 
according to the equation [35,36]: 
(𝑦𝑖 ― 𝑎)
𝑦𝑀𝑆𝐶,𝑖 = 𝑏 
Where : yMSC,i is the corrected spectrum value
 yi is the original spectrum value
      a is the intercept of the line
      b is the slope of the line 
First derivative was corrected both the offset and baseline of the NIR spectra using 
Savitzky-Golay method where a second order polynomial was fitted to the data by 
least square using 13 data points [35]. 
4 
Applied Spectroscopy 
 
  
  
 
 
     
    
  
 
 
  
 
   
  
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Peer Review Version 
Page 5 of 48 
Correlation in Wavenumber Space (CWS) 
CWS method matched the correlation coefficient (r) value of the test spectrum (A) 
and a reference spectrum (B). It was calculated as the momentum product (rp) 
between both spectra according to the equation [35,37]: 
𝑟𝑝 = 
∑(𝐴𝑖 ― 𝐴)(𝐵𝑖 ― 𝐵) 
∑(𝐴𝑖 ― 𝐴)2∑(𝐵𝑖 ― 𝐵)2 
An r value of -1 meant that the spectra were completely dissimilar whereas an r 
value of +1 meant that the spectra were identical. In this work, an r value of 0.95
was taken as a match among products because it was difficult to get +1 among 
identical samples due to noise in the spectra [35,37]. For evaluation of CWS 
method, type I and type II errors were explored [30]. Type I errors (known as false 
positives) were encountered when an authentic antibiotic was misidentified by the 
algorithm (i.e. gave r values < 0.95). On the other hand, type II errors (known as 
false negatives) were encountered when a counterfeit sample were identified as 
authentic (i.e. gave r values > 0.95). 
Principal Component Analysis (PCA) 
PCA classified spectral data by reducing its dimensionality into two subspaces 
being scores and loadings. The scores showed the distribution of the antibiotics in 
multidimensional space and the loadings showed significant absorbance values 
corresponding to the significant constituents (influencers) within the models. PCA 
was applied to the MSC-D1 NIR spectra of the products in order to visualize 
patterns on classification among the products. As with CWS method, PCA was 
evaluated for type I and type II errors [30]. In this case, type I error was 
encountered when an authentic antibiotic was not clustered with authentic 
antibiotics. Moreover, a type II error was encountered when a counterfeit antibiotic 
was clustered with the authentic ones. 
Applied Spectroscopy 
5 
   
   
    
   
     
   
   
  
 
 
   
  
 
 
    
 
 
  
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Peer Review Version 
Page 6 of 48 
Soft Independent Modelling of Class Analogy (SIMCA) 
SIMCA is a chemometric approach, based on PCA, which models the variation 
within the collection of reference spectra for a given material, as well as the
difference between spectra of different materials [38]. This allows SIMCA to be
sensitive to small spectral differences, even batch-to-batch or sampling variations. 
New samples can then be classified to one (or none) of the established class 
models, based on their similarity to the respective model. This is achieved by 
investigating the size of its residual, as well as its location on the scores map. 
Materials and M thods 
Materials 
A total of 23 antibiotic products containing six different APIs were used in this study 
(Table 1). The APIs of the antibiotics included: amoxicillin trihydrate and clavulanic 
acid; azithromycin dihydrate; ciprofloxacin hydrochloride; doxycycline 
hydrochloride and ofloxacin. The antibiotic products were obtained from 11 
different countries: Austria; France; Germany; Ghana; India; Italy; Jordan; 
Lebanon; Spain; UAE and the UK. The products were either tablets or capsules 
and included both branded and generic medicines. Regards the excipients, 19 
products had between seven and 10 excipients each (Table 2). The excipients of 
the remaining four products were not reported. In total, 29 excipients were present 
in at least one or more products (Appendix A). The recurrent excipients were: 
hypromellose, magnesium stearate, maize starch and titanium dioxide. 
Near infrared spectroscopic analysis 
NIR spectra of antibiotic products and their individual constituents were collected 
using the PerkinElmer Spectrum Two NTM FT-NIR instrument equipped with NIR 
reflectance module (NIRM). Tablet formulations were measured as received from 
both sides. The contents of each capsule formulation were emptied into glass vials 
and were measured through the vials. Likewise, excipients were powders and were 
6 
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measured via glass vials. Two spectra were collected per each tablet and three 
spectra per each vial over the wavenumber range of 10,000 – 4000 cm-1 with 
spectral resolution of 8 cm-1. Each spectrum was the sum of 32 scans. 
Data analysis 
Spectra were exported into Matlab R2018b where data pre-treatment was applied. 
Pre-treatment of NIR spectra was made using MSC-D1. Multivariate data analysis 
was conducted using CWS; PCA; and SIMCA methods. CWS was applied to the 
MSC-D1 NIR spectra in Matlab R2018b where the r values of products were 
compared and an r value of 0.95 was considered a threshold. PCA was applied in
Matlab R2018b where clustering among antibiotics was evaluated. SIMCA analysis 
was carried out using PerkinElmer AssureIDTM materials verification software to 
create five PCA models of the antibiotic products. A global PCA of all materials 
was also created to provide an overview of the complete model and understand 
relationships between material types. The threshold taken for inter-material 
distances was 1.5 where a distance below 1.5 was considered a similarity. 
Results and Discussion 
Diversity of the sample set relating to the APIs and excipients 
In order to evaluate the identification potential of the method, 23 antibiotic products 
relating to five APIs were chosen. The products were of both branded and generic 
types, of tablet and/or capsule formulations and were obtained from different 
sources across the wholesale supply chain including community pharmacies, 
hospital pharmacies, humanitarian aid supply, online pharmacies, street market 
and wholesalers (Table 1). The APIs of the evaluated products were: amoxicillin
trihydrate and clavulanic acid (AMC); azithromycin dehydrate (AZ); ciprofloxacin 
hydrochloride (CIP); doxycycline hydrochloride (DOX) and ofloxacin (OFL). The 
numbers of products per antibiotic varied between two and 12 products for each 
API depending on availability and were: Two for each of DOX and OFL, three for 
AMC, four for AZ, and 12 for CIP. In some cases, the aforementioned products had
Applied Spectroscopy 
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overlapping excipients (Table 2). Excipients were always reported for branded but 
not generic products. Where reported, the minimum number of excipients per 
product was six and the maximum was 10. However, in most cases the main 
excipients were consistent among products of the same API. For instance, AMC 
products (AMC1, AMC2 and AMC3) were from three different manufacturers in 
Lebanon, Spain and the UK and had overlapping excipients being: hypromellose, 
microcrystalline cellulose (MCC), magnesium stearate (MgS), and titanium dioxide. 
Likewise, OFL products (OFL1 and OFL2) were from two different manufacturers 
and had six common excipients being: croscarmellose sodium, hypromellose, 
lactose, maize starch, MCC, and titanium dioxide. CIP branded products (CIP1-
CIP5) were all from the same manufacturer and had the same list of excipients. 
Three generic CIP products (CIP7, CIP8, and CIP9) had common excipients as 
branded CIP products being: crospovidone, colloidal anhydrous silica, 
hypromellose, macrogol 4000, maize starch, MgS, MCC, and titanium dioxide. On
the other hand, AZ products (AZ1, AZ2, AZ3, and AZ4) were manufactured by two 
manufacturers and showed different excipients between both manufacturers.
Moreover, CIP11 and CIP12 had different list of excipients to the other CIP 
products. The excipients were not reported for CIP6, CIP10, DOX1, and DOX2 that 
were manufactured by generic manufacturers. 
Spectral evaluation 
The spectra of the antibiotic products showed characteristics for their main 
excipients that were key in identifying the products using NIRS (Appendix B). 
Hence, NIRS offered the advantage of giving more information on the samples’ 
constituents including the API and excipients. Thus, it could serve as a
fingerprinting in spectral identification [39]. This was confirmed when the branded 
medicine of each antibiotic was compared against its main excipient (Figure 1). 
However, the degree of match depended on the amount of API or excipients in the
product. OFL1 showed spectral similarity for MCC and maize starch with 
correlation coefficient (r) values of 0.73 and 0.69 respectively that confirmed that 
these excipients were present in adequate amounts. Likewise, DOX1 showed 
8 
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spectral similarity for MCC and maize starch with r values of 0.71 and 0.75 
respectively. However, excipients that were present in low amounts within a tablet 
did not show peaks in the NIR spectra of the tablets. For instance, talc was present
in OFL1 but no characteristic peak for it was seen within its spectra. 
Authentication of branded antibiotic products 
PCA was successful in showing the chemical variation between different 
antibiotics. The PCA model showed good classification following MSC-D1 
treatment of the NIR spectra of the products. The first three PCs contributed to 
89.2% of the variance with 76.4% of the variance explained by PC1 and PC2. 
Figure 2 shows the 2D and 3D scores plots of AMC1; AZ1; CIP1; DOX1; and OFL1. 
A distinct cluster was observed for each antibiotic product and that showed the
effectiveness of PCA in differentiating between the five authentic products (Figure 
2). The highest variance on PC1 was observed for the CIP1 cluster. This was 
followed by the clusters corresponding to AMC1, DOX1 and OFL1 that were 
neighboring each other. AMC1 and OFL1 contained around 50% of API and 50% 
of excipients. Two excipients were common among both products and were MgS 
and hypromellose. This also could indicate that DOX had similar excipients to AMC
and OFL. To interpret the influences of individual constituents on antibiotic 
products, PC loading plots were visualized. Figure 3 shows the PC1 loading plot 
of the different antibiotic PCA model that corresponded to 51.2% of the variance.
The aforementioned PC1 loading showed contribution over the wavenumber 
ranges of 9172-8124 cm-1; 7572-6502 cm-1; 6260-5632 cm-1; 5340-4880 cm-1; and 
4752-4016 cm-1. The aforementioned five regions showed spectral features 
corresponding to MgS; ciprofloxacin and MCC; ciprofloxacin and lactose; 
amoxicillin and ciprofloxacin (Appendix B). This suggested that the five antibiotic 
products could be principally separated on the basis of differences in their APIs
and excipients. 
Taking the aforementioned model forward, the next step was to classify the
branded and generic medicines for each antibiotic and look into tracking their 
manufacturing sources (Figures 4 and 5). The discriminative capability of PCA 
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depended on sample size and sample type [37]. For both AMC and AZ products, 
two distinct clusters were seen between the branded and generic products (Figure 
4 a and b). AMC1, AMC2, and AMC3 showed three distinct clusters that confirmed 
their three distinct manufacturing sources being the UK, Lebanon, and Spain. The
PC1 loading (95.2% of the variance) showed characteristic features for amoxicillin, 
MCC and talc (Appendix A, Appendix B). Amoxicillin spectral features were seen 
in the regions of 8910-8378 cm-1; 6178-5636 cm-1; and 5334-5082 cm-1. Talc 
spectral features were featured at 7318-6992 cm-1; whereas MCC spectral features 
were seen at 4550-4000 cm-1. Moreover, the PCA scores plot of AZ showed three 
distinct clusters that corresponded to both their manufacturing sources and 
formulation type. In this respect, AZ3 and AZ4 products were clustered together 
where both products were capsules and manufactured by the same manufacturer. 
Two distinct clusters were seen for AZ1 and AZ2 which were both of tablet
formulation but manufactured by two different manufacturers. It is noteworthy to
mention here that AZ2 had the same manufacturer as AZ3 and AZ4 but was of 
tablet instead of capsule formulation. This confirmed the ability of NIR to distinguish 
physical differences between samples of the same chemical makeup [40]. The PC1 
loading plot of AZ products (75.2% of the variance) 7270-7138 cm-1 corresponding
to talc that was an excipient in AZ1 (of tablet formulation) (Appendix A). Additional 
spectral features in the PC1 loading plot were seen in the regions of 8804-8350 
cm-1; 7074-6800 cm-1; 6584-6290 cm-1; 6064-5646 cm-1; 5334-5004 cm-1; 4984-
4668 cm-1; and 4550-4668 cm-1. The aforementioned seven regions corresponded 
to lactose. DOX products scores plot showed type I error in the cluster of one 
product (Figure 4c). Hence, DOX1 and DOX2 products were separated in three
clusters (instead of two) where DOX1 was separated in two distinct clusters. The 
PC1 loading of DOX products (90.7% of the variance) showed characteristic 
features for talc in the region of 7242-7088 cm-1. Other features for this PC1 loading 
were seen in the region of 6156-5670 cm-1; 5348-4750 cm-1; and 4650-4000 cm-1. 
The aforementioned three regions corresponded to lactose and MCC. 
Nonetheless, OFL1 and OFL2 products were clustered into two distinct clusters 
that corresponded to their manufacturing sources being the UK and France 
respectively (Figure 4d). However, type I error was encountered in this latter PCA 
10 
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score plot where both products had outlier(s) within their score plot. The PC1 
loading (82.9% of the variance) of OFL products showed characteristic spectral 
features for talc in the region of 7246-7136 cm-1. Additional peaks were seen in the 
regions of 6170-5598 cm-1; 5312-5124 cm-1; and 4752-4000 cm-1. The
aforementioned three regions corresponded to lactose. 
In addition to identifying manufacturing source and discriminating branded from 
generic medicines; the potential for NIR and PCA for spotting a potential counterfeit 
product was demonstrated through the PCA scores plot of CIP products (Figure 
5). In this sense, the PCA score of a CIP branded product (CIP5) overlapped with 
one of the generic products. In order to address this overlap, the PC1 loading 
(67.8% of the variance) of the CIP products had been examined and had shown a
major influence of 7260-7150 cm-1 that is characteristic for talc [41]. It is noteworthy 
to mention in this case that talc was not listed in the label claim of any of the 
branded products. Talc had been found in counterfeit antibiotics as it is cheap and 
increases the bulk of the medicine [20, 42]. Therefore, CIP5 did not match the 
manufacturers’ specification relating to the identity and could be counterfeit [30].  
Development of SIMCA classification models 
To further address the type I error encountered with PCA, PCA was taken forward 
and SIMCA models were constructed. The first SIMCA model showed agreement 
with PCA Model 1. Hence, distinct classification of the five branded products was 
observed with no overlapping materials. SIMCA provided a further advantage over 
PCA in detecting type I and type II errors in classification of different products [43].
In this respect, the distances between the five products were calculated and were 
found above zero and this showed no type I or type II errors (Table 3). Hence table
3 showed all distances above the threshold that was 1.5. Successively, individual 
SIMCA models were applied to each antibiotic (Figure 6). For AMC products, the
global PCA showed three distinct PCs for AMC1, AMC2, and AMC3 that confirmed 
their different manufacturing sources. The four AZ products showed three distinct 
clusters: one corresponding to AZ1, second to AZ2, and the third to AZ3 and AZ4. 
AZ3 and AZ4 were of the same formulation (both capsules) and had the same 
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manufacturer but purchased in different countries; therefore, SIMCA was further 
successful in detecting differences in manufacturing sources and formulation. On 
the other hand, misclassification was observed among CIP branded and generic 
products where no clear clustering was observed between both groups of products. 
Two products were misclassified and seen as two distinct clusters (CIP 6 and CIP 
10) and that denoted type I error. Moreover, the aforementioned model could not 
distinguish the counterfeit CIP batch (CIP 5) that indicated type II error. Likewise, 
type I error was observed for DOX global PCA where DOX1 was scattered in two 
distinct clusters. On the other hand, OFL1 and OFL2 products were separated 
between two individual clusters that corresponded to their different manufacturing 
sources. 
Conclusion 
The findings of the study demonstrated the effectiveness of portable NIRS and 
chemometrics as a tool in authenticating antibiotics. The combination of NIRS with 
PCA and SIMCA proved to be efficient in discriminating branded from generic 
medicines and in tracking the manufacturing sources of medicines. Moreover, the 
algorithms could give initial indication for the presence of a potential counterfeit. 
However, some limitations were encountered in this study. The first limitation 
related to sample size and sourcing of the samples that had been a challenge 
especially that the medicines had been sought from different countries. The second 
limitation related to the precision of classifying authentic products particularly with 
large datasets with overlapping excipients such as CIP. Other limitations were 
associated with the sensitivity of NIRS for characterizing constituents where 
constituents with low amounts in a medicine will not show spectral features. In 
summary, portable NIRS could serve as an initial screening method for 
authentication of antibiotics saving time and money associated with importing the 
samples to the laboratory. However, for identity confirmation of the API in 
antibiotics more quantitative techniques are needed. 
12 
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List of tables 
Table 1. Details of the antibiotics used in the study 
AN API Dose B/G Manufacturing Source Formulation 
(mg) place type 
Peer Review Version 
AMC1 amoxicillin 
trihydrate/ 
clavulanic acid 
500/ 
125 
B UK Lebanon/ 
Community 
pharmacy 
tablet 
AMC2 amoxicillin 
trihydrate/ 
clavulanic acid 
500/ 
125 
G Lebanon Lebanon/ 
Humanitarian 
aid 
tablet 
AMC3 amoxicillin 
trihydrate/ 
clavulanic acid 
500/ 
125 
G Spain Lebanon/ 
Humanitarian 
aid 
tablet 
AZ1 azithromycin 
dihydrate 
250 G UK UK/ 
wholesaler 
tablet 
AZ2 azithromycin 
dihydrate 
250 B Italy Italy/ 
wholesaler 
tablet 
AZ3 azithromycin 
dihydrate 
250 B Italy Italy/ 
wholesaler 
capsule 
AZ4 azithromycin 
dihydrate 
250 B Italy Italy/ 
wholesaler 
capsule 
CIP1 ciprofloxacin 
hydrochloride 
500 B Germany UK/ 
wholesaler 
tablet 
CIP2 ciprofloxacin 
hydrochloride 
500 B Germany UK/ 
wholesaler 
tablet 
CIP3 ciprofloxacin 
hydrochloride 
750 B Germany UK/ online 
pharmacy 
tablet 
CIP4 ciprofloxacin 
hydrochloride 
500 B Germany UK/ online 
pharmacy 
tablet 
CIP5 ciprofloxacin 
hydrochloride 
250 B Germany UK/ online 
pharmacy 
tablet 
CIP6 ciprofloxacin 
hydrochloride 
500 G Ghana Ghana/ 
street market 
tablet 
CIP7 ciprofloxacin 
hydrochloride 
500 G UAE Saudi 
Arabia/ 
hospital 
pharmacy 
tablet 
CIP8 ciprofloxacin 
hydrochloride 
500 G India UK/ 
wholesaler 
tablet 
CIP9 ciprofloxacin 
hydrochloride 
500 G UK UK/ 
community
pharmacy 
tablet 
CIP10 ciprofloxacin 
hydrochloride 
250 G India Lebanon/ 
Humanitarian 
aid 
tablet 
CIP11 ciprofloxacin 
hydrochloride 
500 G UK UK/ 
community
pharmacy 
tablet 
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CIP12 ciprofloxacin 500 G UK UK/ 
community 
pharmacy 
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tablet 
hydrochloride 
DOX1 doxycycline 100 G Jordan Lebanon/ capsule 
hydrochloride Humanitarian 
aid 
DOX2 doxycycline 100 G Austria capsule 
hydrochloride 
OFL1 ofloxacin 200 G UK tablet 
wholesaler 
OFL2 ofloxacin 200 B France 
Lebanon/ 
community
pharmacy 
UK/ 
UK/ tablet 
wholesaler 
AM: Amoxicillin, API: Active pharmaceutical ingredient, AZ: Azithromycin, B: Branded, G: Generic, CIP: Ciprofloxacin, DOX:
Doxycycline, OFL: Ofloxacin, UAE: United Arab Emirates. 
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Table 2. List of excipients studied in the investigated antibiotics 
Excipient/AN AMC AMC AMC AZ AZ AZ AZ CIP CIP CIP CIP CIP CIP CIP CIP CIP CIP1 CIP1 CIP1 DOX DOX OFL OFL 
1 2 3 1 2 3 4 1 2 3 4 5 6 7 8 9 0 1 2 1 2 1 2 
Butyl hydroxy toluene 
Calcium hydrogen 
phosphate 
Carmellose NS300 
Colloidal  silicon 
dioxide 
Croscarmellose sodium 
Crospovidone 
Dimethicone 
Peer Review Version
Ethanol 96% 
Ethyl cellulose 
Gelatin 
Hyprolose 
Hypromellose 
Lactose monohydrate 
Macrogol 3000 
Macrogol 4000 
Macrogol 6000 
Macrogol 8000 
Maize starch 
MCC 
MgS 
Propylene glycol 
Sodium citrate 
Sodium lauryl sulfate 
Sodium starch 
glycolate 
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
1
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4
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7
8
9
10
11
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29
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32
33
34
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41
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Sodium stearyl 
fumarate 
Talc 
Titanium dioxide 
Triacetin 
                       
                       
                       
                       
                       
 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
Triethyl citrate 
Total number of 9 10 10 6 6 6 6 8 8 8 8 8 NR 9 8 8 NR 7 7 NR NR 9 9 
excipients 
AMC: amoxiciilin/clavulanic acid; AN: antibiotic number; AZ: azithromycin; CIP: ciprofloxacin, DOX: doxycycline; MgS: magnesium stearate; MCC: microcrystalline cellulose; NR: not reported; OFL: 
ofloxacin 
Table 3. Inter-material distances explained by the SIMCA models. 
Material Doxycycline Ofloxacin Ciprofloxacin Amoxycillin Azithromycin 
Doxycycline - 24 30.5 28.2 28.7 
Ofloxacin 24 - 28.1 19.3 16.3 
Ciprofloxacin 30.5 28.1 - 25.4 34.5 
Amoxicillin 28.2 19.3 25.4 - 23.5 
Azithromycin 28.7 16.3 34.5 23.5 -
Applied Spectroscopy 
21 
  
 
 
   
 
 
 
  
  
  
  
 
 
 
  
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Peer Review Version 
Page 22 of 48 
Figure captions 
Figure 1. MSC-D1 NIR spectra of (a) amoxicillin/clavulanic acid; (b) azithromycin; (c) 
ciprofloxacin; (d) doxycycline; (e) ofloxacin branded antibiotic products and their main 
excipients including (f) lactose; (g) maize starch; (h) MCC; and (i) talc measured using the 
PerkinElmer Spectrum Two N FT-NIR instrument equipped with NIRM. 
Figure 2. (a) Two-dimensional and (b) three-dimensional PCA scores plots of the MSC-D1
NIR spectra of branded antibiotic products of amoxicillin/clavulanic acid (blue), azithromycin 
(red), ciprofloxacin (green), doxycycline (cyan), and ofloxacin (black) measured using the 
PerkinElmer Spectrum Two N FT-NIR instrument equipped with NIRM. 
Figure 3. PC1 loading plot of the different brands that contributed to 51.2% of the variance
among the data. 
Figure 4. PCA scores plots of the MSC-D1 spectra of antibiotics products including (a) 
amoxicillin/clavulanic acid, (b) azithromycin, (c) doxycycline, and (d) ofloxacin measured using 
the PerkinElmer Spectrum Two N FT-NIR instrument equipped with NIRM. The first three PCA 
scores plots were two-dimensional whereas the latter score plot was three-dimensional. 
Figure 5. PCA scores plot of the MSC-D1 NIR spectra of branded (blue) and generic (red) 
ciprofloxacin batches measured using the PerkinElmer Spectrum Two N FT-NIR instrument 
equipped with NIRM. 
Figure 6. SIMCA models of the MSC-D1 spectra of antibiotics products including (a) 
amoxicillin/clavulanic acid, (b) azithromycin, (c) ciprofloxacin, (d) doxycycline, and (e) 
ofloxacin measured using the PerkinElmer Spectrum Two N FT-NIR instrument equipped with 
NIRM. 
22 
Applied Spectroscopy 
 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Peer Review Version
Page 23 of 48 
338x190mm (96 x 96 DPI) 
Applied Spectroscopy 
 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Peer Review Version
Page 24 of 48 
260x126mm (600 x 600 DPI) 
Applied Spectroscopy 
 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Peer Review Version
Page 25 of 48 
Figure 2. PCA scores plot of the MSC-D1 spectra of branded antibiotic products of amoxicillin/clavulanic acid 
(blue), azithromycin (red), ciprofloxacin (green), doxycycline (cyan) and ofloxacin (black) measured using 
the PerkinElmer Spectrum Two N FT-NIR instrument equipped with NIRM. 
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Figure 3. PC1 loading plot of the different brands that contributed to 51.2% of the variance among the data. 
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Figure 4. PCA scores plots of the MSC-D1 spectra of antibiotics products including (a) amoxicillin/clavulanic 
acid, (b) azithromycin, (c) doxycycline and (d) ofloxacin measured using the PerkinElmer Spectrum Two N 
FT-NIR instrument equipped with NIRM. 
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Figure 5. PCA scores plot of the MSC-D1 NIR spectra of branded (blue) and generic (red) ciprofloxacin
batches measured using the PerkinElmer Spectrum Two N FT-NIR instrument equipped with NIRM. 
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Figure 6. SIMCA models of the MSC-D1 spectra of antibiotics products including (a) amoxicillin/clavulanic 
acid, (b) azithromycin, (c) ciprofloxacin, (d) doxycycline and (e) ofloxacin measured using the PerkinElmer 
Spectrum Two N FT-NIR instrument equipped with NIRM. 
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1 
2 
3 Appendix A PCA loading plots of the antibiotic products 4 
6 
7 
8 A1. List of excipients present in the products: 
9 Butyl hydroxyl toluene; calcium hydroxyl toluene; carmellose NS300; colloidal silicon 
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Figure A2. PC1 loading plot of the PCA of the MSC-D1 NIR spectra of AZ products 
26 that contributed to 75.2% of the variance among the data. 
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Figure A3. PC1 loading plot of the PCA of the MSC-D1 NIR spectra of DOX products 
that contributed to 90.7% of the variance among the data. 
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Figure A4. PC1 loading plot of the PCA of the MSC-D1 NIR spectra of OFL products 
Figure A5. PC1 loading plot of the PCA of the MSC-D1 NIR spectra of CIP products 
that contributed to 67.8% of the variance among the data. 
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Figure B1. MSC-D1 NIR spectrum of AMC1 products measured using the Perkin Elmer 
Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B3. MSC-D1 NIR spectrum of AMC2 products measured using the Perkin Elmer 
26 Spectrum Two FT-NIR instrument quipped with NIRM. 
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FigureB 4. MSC-D1 NIR spectrum of AZ1 products measured using the Perkin Elmer 
Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B5. MSC-D1 NIR spectrum of AZ2 products measured using the Perkin Elmer 
26 Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B6. MSC-D1 NIR spectrum of AZ3 products measured using the Perkin Elmer 
Spectrum Two FT-NIR instrument equipped with NIRM. 
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Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B7. MSC-D1 NIR spectrum of AZ4 products measured using the Perkin Elmer 
Figure B8. MSC-D1 NIR spectrum of CIP1 products measured using the Perkin Elmer 
Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B9. MSC-D1 NIR spectrum of CIP2 products measured using the Perkin Elmer 
26 Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B10. MSC-D1 NIR spectrum of CIP3 products measured using the Perkin Elmer 
Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B11. MSC-D1 NIR spectrum of CIP4 products measured using the Perkin Elmer 
26 Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B12. MSC-D1 NIR spectrum of CIP5 products measured using the Perkin Elmer 
Spectrum Two FT-NIR instrument equipped with NIRM. 
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Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B13. MSC-D1 NIR spectrum of CIP6 products measured using the Perkin Elmer 
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Figure B14. MSC-D1 NIR spectrum of CIP7 products measured using the Perkin Elmer 
Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B16. MSC-D1 NIR spectrum of CIP9 products measured using the Perkin Elmer 
Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B15. MSC-D1 NIR spectrum of CIP8 products measured using the Perkin Elmer 24 
Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B17. MSC-D1 NIR spectrum of CIP10 products measured using the Perkin Elmer 
Spectrum Two FT-NIR instrument equipped with NIRM. 
Figure B18. MSC-D1 NIR spectrum of CIP11 products measured using the Perkin Elmer 
Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B19. MSC-D1 NIR spectrum of CIP12 products measured using the Perkin Elmer 
26 Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B20. MSC-D1 NIR spectrum of DOX1 products measured using the Perkin Elmer 
Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B21. MSC-D1 NIR spectrum of DOX2 products measured using the Perkin Elmer 
Spectrum Two FT-NIR instrument equipped with NIRM. 
Figure B22. MSC-D1 NIR spectrum of OFL1 products measured using the Perkin Elmer 
Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B23. MSC-D1 NIR spectrum of OFL2 products measured using the Perkin Elmer 
Figure B24. MSC-D1 NIR spectrum of amoxicillin trihydrate API measured using the Perkin 
Elmer Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B25. MSC-D1 NIR spectrum of ciprofloxacin hydrochloride API measured using the 
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Elmer Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B27. MSC-D1 NIR spectrum of hydroxyl propyl methyl cellulose measured using the
Perkin Elmer Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B28. MSC-D1 NIR spectrum of lactose monohydrate measured using the Perkin 
51 Elmer Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B30. MSC-D1 NIR spectrum of microcrystalline cellulose measured using the Perkin 
Elmer Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B29. MSC-D1 NIR spectrum of maize starch measured using the Perkin Elmer 28 
29 Spectrum Two FT-NIR instrument equipped with NIRM. 
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Figure B31. MSC-D1 NIR spectrum of magnesium stearate measured using the Perkin 
Figure B32. MSC-D1 NIR spectrum of talc measured using the Perkin Elmer Spectrum Two 
FT-NIR instrument equipped with NIRM. 
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